Jump to:
Oxford Nanopore Technologies PLC Fundamentals
| Company Name | Oxford Nanopore Technologies PLC | Last Updated | 2025-05-02 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 955.447 m | Market Cap | £1.18 bn |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.16 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0619 | Debt Equity Ratio | 0.0693 |
|---|
| Asset Equity Ratio | 1.2656 | Cash Equity Ratio | 0.5771 |
|---|
| Quick Ratio | 3.4347 | Current Ratio | 4.66 |
|---|
| Price To Book Value | 2.0239 | ROCE | 0 |
|---|
Oxford Nanopore Technologies PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Oxford Nanopore Technologies PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|
| Tangible Assets | £101.19 m | £82.42 m | £63.20 m |
| Intangible Assets | £43.81 m | £32.91 m | £30.04 m |
| Investments | £74.31 m | £209.07 m | £84.97 m |
| Total Fixed Assets | £221.96 m | £329.88 m | £185.89 m |
| Stocks | £99.45 m | £101.55 m | £87.70 m |
| Debtors | £44.56 m | £42.33 m | £46.97 m |
| Cash & Equivalents | £338.37 m | £270.05 m | £476.19 m |
| Other Assets | £2.64 m | £5.49 m | £7.68 m |
| Total Assets | £742.05 m | £777.06 m | £823.89 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|
| Creditors within 1 year | £111.49 m | £89.20 m | £91.54 m |
| Creditors after 1 year | £44.22 m | £44.01 m | £38.80 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £155.71 m | £133.21 m | £130.33 m |
| Net assets | £586.34 m | £643.85 m | £693.56 m |
| Equity | 2024 | 2023 | 2022 |
|---|
| Called up share capital | £96,000.00 | £86,000.00 | £83,000.00 |
| Share Premium | £779.70 m | £698.55 m | £627.56 m |
| Profit / Loss | -£139.96 m | -£149.77 m | -£83.41 m |
| Other Equity | £586.34 m | £643.85 m | £693.56 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £586.34 m | £643.85 m | £693.56 m |
| Ratios | 2024 | 2023 | 2022 |
|---|
| Debt Ratio | £0.06 | £0.05 | £0.04 |
| Debt-to-Equity | £0.07 | £0.06 | £0.04 |
| Assets / Equity | 1.2656 | 1.2656 | 1.2656 |
| Cash / Equity | 0.5771 | 0.5771 | 0.5771 |
| EPS | -£0.16 | -£0.19 | -£0.12 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|
| Cash from operating activities | -£109.89 m | -£137.30 m | -£63.83 m |
| Cashflow before financing | -£36.30 m | -£72.57 m | -£77.54 m |
| Increase in Cash | -£21.28 m | -£134.36 m | -£128.90 m |
| Income | 2024 | 2023 | 2022 |
|---|
| Turnover | £183.19 m | £169.67 m | £198.60 m |
| Cost of sales | £77.80 m | £79.19 m | £74.79 m |
| Gross Profit | £105.39 m | £90.48 m | £123.81 m |
| Operating Profit | -£152.33 m | -£168.61 m | -£98.48 m |
| Pre-Tax profit | -£139.96 m | -£149.77 m | -£83.41 m |
Oxford Nanopore Technologies PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. |
|---|
| Latest Interim Date | 3 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 4 Mar 2025 |
|---|
Oxford Nanopore Technologies PLC Directors
| Appointed | Name | Position |
|---|
| 2025-04-30 | Mr. Adrian Nevil Hennah | Non-Executive Director |
| 2022-04-12 | Mr. Alan John Aubrey | Non-Executive Director |
| 2025-04-30 | Mr. Duncan Eden Tatton-Brown | Non-Executive Director,Chairman |
| 2025-03-12 | Mr. John O'Higgins | Non-Executive Director |
| 2025-04-30 | Ms. Wendy Becker | Non-Executive Director,Senior Independent Director |
| 2022-06-30 | Mr. Peter Vance Allen | Non-Executive Director,Chairman |
| 2025-04-14 | Mr. Nicholas Patrick Keher | Executive Director,Chief Financial Officer |
| 2024-04-30 | Mrs. Sarah Gordon Wild | Non-Executive Director |
| 2025-04-30 | Dr. Gurdial Sanghera | Executive Director,Chief Executive Officer |
| 2024-06-10 | Mr. Clive Gavin Brown | Executive Director,Chief Technology, Innovation and Product Officer |
| 2024-06-10 | Mr. Timothy Cowper | Executive Director,Chief Financial Officer |
| 2024-06-10 | Dr. James Willcocks | Executive Director,Chief Business Development Officer |
| 2025-03-26 | Ms. Katherine Sophie Priestman | Non-Executive Director,Senior Independent Director |
Oxford Nanopore Technologies PLC Contact Details
Oxford Nanopore Technologies PLC Advisors
